A randomized, double‐blind, single‐dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab - Schwabe, C.; Cole, A.; Espigares‐Correa, A.; Beydon, M. E.; Florez‐Igual, A.; Queiruga‐Parada, J. (Pharmacology research & perspectives, 2023)
Keywords: Administration, Intravenous; Antibodies; bevacizumab; Bevacizumab - adverse effects; Bevacizumab - pharmacokinetics; Bioequivalence; Biological products; biosimilar; Biosimilar Pharmaceuticals; Blood & organ donations; clinical trial; Clinical trials; Double-Blind Method; Double-blind studies; Drug dosages; Electrocardiography; Humans; Male; Manufacturing; MB02; Medical laboratories; Monoclonal antibodies; Original; Pharmacokinetics; Pharmacology; Phlebotomy; Proteins; safety; Schedules; Software; Therapeutic Equivalency; Vascular endothelial growth factor; Vital signs; United States--US; clinical trial; bevacizumab; pharmacokinetics; MB02; safety; biosimilar